Congratulations to all authors.
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development - The AAPS Journal
| SpringerLink |
remove preview |
|
| Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development - The AAPS Journal |
| A survey conducted by the Therapeutic Product Immunogenicity (TPI) community within the American Association of Pharmaceutical Scientists (AAPS) posed questions to the participants on their immunogenicity risk assessment strategies prior to clinical development. |
| View this on SpringerLink > |
|
|
------------------------------
Yi Wen Ph.D.
Sr. Director
Eli Lilly and Company
Indianapolis IN
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------